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ABSTRACT
Germany has been an immigration country since the early
1950s. In December 2007, 6.7 million non-German citizens
lived in the country. However, the total number of citizens
with a migration background is 15–20 million, about
9 million of whom come from countries where sickle cell
disease and thalassaemias are frequent. In a country with
82 million inhabitants health authorities are not worried by
the presence of probably 1000–1500 sickle cell and 450
transfusion-dependent thalassaemia patients, and therefore
no screening or preventive measures have been taken so far
on a national scale. There are plans for a pilot project
(1 year) to screen all newborns for sickle cell disease in
obstetric hospitals in 4–5 cities with more than 20%
migrants. Funding and lack of an infrastructure to provide
counselling are major problems.
Immigration from the Mediterranean Basin to
Germany started in the early 1950s, and from
Africa in the early 1980s. In November 2007
(Federal Statistics Bureau in Wiesbaden) 6.7 million
immigrants without a German passport were living
in Germany (82 million inhabitants): 1.7 million
from Turkey, approximately 820 000 from Italy and
Greece, 250 000 from the Middle East, approxi-
mately 120 000 from North Africa (Maghreb), and
110 000 from Sub-Saharan Africa. However, the
total number of citizens with an immigration
background was 15–20 million, 9 million of whom
came from countries where haemoglobinopathies
and thalassaemias are frequent. Numbers of new
diagnoses of sickle cell disease at the major
haemoglobin laboratory in Germany (Professor E
Kohne, Ulm, Germany) over the last 10 years
suggest that, in 2008, at least 1000–1500 patients
with sickle cell disease are living in Germany. There
are 450–500 patients with transfusion-dependant
beta thalassaemia. We have no figures for individuals
with alpha thalassaemia syndromes.
In 1987 we established a voluntary register for
paediatric sickle cell patients, provided physicians
with up-to-date information about sickle cell disease
and established an information centre for haemoglo-
bin disorders. Since 1987, 582 patients with all
known genotypes have been registered. In June 2008
there were 288 patients being followed at 92
hospitals or private practices in our register: 75%
children, 25% adults. The majority of paediatric
patients still under follow-up in the register are from
Sub-Saharan Africa, while most of the registered
adult patients have a Mediterranean background.
Neonatal screening for sickle cell disease is not
yet done in Germany on a national level. Diagnosis
depends on the astuteness and knowledge
of individual physicians. As a result of our
information efforts since 1987, paediatricians are
fairly well informed about sickle cell disease.
Young adults however face enormous problems
of transition into adult medicine as very few
internists are familiar with sickle cell disease.
There is one hospital in Germany (Obstetric
Department, University Hospital Munich;
Professor O Genzel-Boroviczeny) where limited
directed neonatal screening, initiated because of a
personal interest, has been done since 2004: all
newborns of Sub-Saharan-African mothers are
screened for sickle cell disease, without having
information about carrier status of the mother, or
ethnic background or carrier status of the father.
From July 2004 to May 2008, 306 newborns of
African mothers were screened. Heel stick blood on
Guthrie cards was used and examined by high-
performance liquid chromatography at the
Hemoglobin Laboratory, Ulm (Professor E Kohne).
One baby had sickle cell anaemia (0.3%) and was
referred to the University Children’s Hospital
Munich. Twent-eight babies were heterozygous
carriers of haemoglobin S (9.2%) and eight were
heterozygous carriers of haemoglobin C (2.6%).
Mothers of heterozygous babies were informed
about the screening result whenever they could be
reached. Obviously newborns with sickle cell disease
born to Turkish, Greek, Sicilian, Middle-Eastern and
North African mothers would have been missed.
In Germany, screening for sickle cell disease
needs to be universal, as it is impossible to elicit a
precise ethnic family history for each pregnant
woman and her partner. About 50% of our sickle
cell patients in Germany are Caucasians from a
wide spectrum of origins; many young adult
carriers are third generation immigrants and there
is a high rate of migrant–German intermarriage.
The authors know blond and blue-eyed sickle cell
carriers with German last names.
Until now sickle cell disease has not been
recognised as a public health problem because of
the relatively small number of sickle cell patients
(1000–1500) in a country of 82 million inhabitants.
There is no antenatal screening for thalassaemias
and sickle cell disease. We are going to propose a pilot
study to the national newborn-screening committee
that includes universal newborn screening for
haemoglobin disorders in obstetric services in cities
with a migrant population of .20% (Berlin,
Frankfurt, Offenbach, Stuttgart, Mannheim and
Munich). Difficulties to be encountered will be
funding, but most of all the lack of any infrastruc-
ture for counselling parents of newborns with
hemoglobin diseases or trait, as there is not yet any
general awareness of haemoglobinopathies.
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